<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties manuscript?><front><journal-meta><journal-id journal-id-type="nlm-journal-id">101730510</journal-id><journal-id journal-id-type="pubmed-jr-id">47794</journal-id><journal-id journal-id-type="nlm-ta">Ophthalmol Glaucoma</journal-id><journal-id journal-id-type="iso-abbrev">Ophthalmol Glaucoma</journal-id><journal-title-group><journal-title>Ophthalmology. Glaucoma</journal-title></journal-title-group><issn pub-type="ppub">2589-4234</issn><issn pub-type="epub">2589-4196</issn></journal-meta><article-meta><article-id pub-id-type="pmid">32841767</article-id><article-id pub-id-type="pmc">7897750</article-id><article-id pub-id-type="doi">10.1016/j.ogla.2020.08.010</article-id><article-id pub-id-type="manuscript">NIHMS1635596</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Cost-Related Medication Non-Adherence in a Nationally Representative U.S. Population with Self-Reported Glaucoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Divakar</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ehrlich</surname><given-names>Joshua R.</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Newman-Casey</surname><given-names>Paula Anne</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Stagg</surname><given-names>Brian</given-names></name><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A5">5</xref></contrib></contrib-group><aff id="A1"><label>1</label>Duke Eye Center, Duke University Medical Center, Durham</aff><aff id="A2"><label>2</label>Center for Eye Policy &#x00026; Innovation, Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan, USA</aff><aff id="A3"><label>3</label>Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan, USA</aff><aff id="A4"><label>4</label>John Moran Eye Center, Department of Ophthalmology and Visual Sciences, University of Utah, Salt Lake City, Utah, USA</aff><aff id="A5"><label>5</label>Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA</aff><author-notes><corresp id="CR1"><bold>Corresponding Author:</bold> Divakar Gupta, 2351 Erwin Rd, Durham, NC USA 27705, Phone: (919) 681-8636, FAX: (919) 681-8267, <email>dg46@duke.edu</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>18</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>22</day><month>8</month><year>2020</year></pub-date><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2021</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>3</month><year>2022</year></pub-date><volume>4</volume><issue>2</issue><fpage>126</fpage><lpage>130</lpage><!--elocation-id from pubmed: 10.1016/j.ogla.2020.08.010--><abstract id="ABS1"><sec id="S1"><title>Purpose:</title><p id="P1">To determine the rates of cost-related non-adherence to medications among U.S. adults with glaucoma and to determine if participants with glaucoma have more cost-related medication non-adherence than those without glaucoma</p></sec><sec id="S2"><title>Design:</title><p id="P2">Cross-sectional study</p></sec><sec id="S3"><title>Participants:</title><p id="P3">Participants in the 2016&#x02013;2017 National Health Interview Survey (NHIS), a cross-sectional survey regarding health topics that is administered annually to a nationally representative sample of non-institutionalized adults in the U.S.</p></sec><sec id="S4"><title>Methods:</title><p id="P4">We calculated proportions of NHIS participants with and without self-reported glaucoma who reported cost-related non-adherence over the previous 12 months. We analyzed responses to 7 survey items that dealt with medication cost-related issues to any/all of a participants&#x02019; medication: Couldn&#x02019;t afford a prescribed medication; Skipped medication doses to save money; Took less medicine to save money; Delayed filling a prescription to save money; Asked doctor for lower cost medication to save money; Bought prescription drugs from another country to save money; Used alternative therapies to save money. We performed univariable and multivariable logistic regression to evaluate the association between self-reported glaucoma diagnosis and responses to these selected questions.</p></sec><sec id="S5"><title>Main Outcome Measures:</title><p id="P5">Proportion of participants with and without self-reported glaucoma who reported cost-related non-adherence.</p></sec><sec id="S6"><title>Results:</title><p id="P6">Participants with glaucoma reported they could not afford prescribed medication more frequently than participants without glaucoma (8.2% vs 6.4% p=0.024). Adjusted predicted proportions from a multivariable model demonstrated that participants with glaucoma responded that they had greater cost-related barriers to medication access.</p></sec><sec id="S7"><title>Conclusions:</title><p id="P7">In this nationally representative sample of the U.S. population, after adjustment for confounding variables, participants with glaucoma more frequently reported cost-related non-adherence to medications compared to participants without glaucoma. Providers prescribing medication to patients with glaucoma should be aware of these findings and consider the impact of medication cost on their patients&#x02019; ability to adhere to therapy.</p></sec></abstract></article-meta></front><body><sec id="S8"><title>Introduction</title><p id="P8">The management of glaucoma, like many chronic diseases, involves the use of long-term medications. In glaucoma care, this typically involves the use of topical eye drops; these topical eye drops decrease the risk of glaucomatous progression and irreversible vision loss.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Unfortunately, patient adherence to glaucoma eye drops is poor.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref></sup></p><p id="P9">Worldwide, medical glaucoma treatment is costly to patients with annual topical eyedrops amounting to a significant portion of their median household income.<sup><xref rid="R4" ref-type="bibr">4</xref></sup> In previous qualitative interview studies, cost has been identified as a barrier to accessing glaucoma medication.<sup><xref rid="R5" ref-type="bibr">5</xref>&#x02013;<xref rid="R9" ref-type="bibr">9</xref></sup> While prior research suggests that cost plays an important role in medication adherence for patients with glaucoma, it is not known on a national level what proportion of patients with glaucoma have cost-related issues with medication adherence. Further, it is not known how challenges regarding the cost of medication compares between patients with and without glaucoma. Understanding how cost affects glaucoma patient mediation adherence is important to policy makers and doctors who take care of patients with glaucoma.</p><p id="P10">In the present study, we present nationally representative rates of cost-related non-adherence for adults with glaucoma in the U.S. We also tested the hypothesis that people with glaucoma have more cost-related challenges to medication adherence than those without glaucoma.</p></sec><sec id="S9"><title>Methods</title><sec id="S10"><title>Data and Analysis Sample</title><p id="P11">We used data from participants 40 years and older from the National Health Interview Survey (NHIS) taken during the years 2016 and 2017 where questions related to eye health and visual function were included. Secondary analysis of this public dataset (NHIS) was approved by the University of Utah&#x02019;s IRB. We excluded participants under 40 years of age to focus on the age range of participants at greatest risk for glaucoma. NHIS is a cross-sectional survey of the US population administered by the U.S. Bureau of the Census. Data from 2016 and 2017 were pooled using the methods recommended by NHIS; we treated pooled data as one large sample, as the samples for 2016 and 2017 were from the same geographic areas with the same sample design, did not overlap, and the variables used for variance estimation were the same for both years of NHIS data.<sup><xref rid="R10" ref-type="bibr">10</xref></sup></p></sec><sec id="S11"><title>Variable Definitions</title><p id="P12">The outcome variables were self-reported responses to yes/no items in NHIS which assessed cost-related barriers to medication adherence over the previous 12 months: Couldn&#x02019;t afford a prescribed medication; Skipped medication doses to save money; Took less medicine to save money; Delayed filling a prescription to save money; Asked doctor for lower cost medication to save money; Bought prescription drugs from another country to save money; Used alternative therapies to save money. For comparison, we aggregated the number of positive responses per participant for the five NHIS statements that directly dealt with difficulties affording medications (couldn&#x02019;t afford prescription medication, skipped medication doses to save money, took less medication to save money, delayed filling med to save money, or used alternative therapies to save money). Participants with glaucoma were identified in NHIS based on self-report of a having been &#x0201c;Told you have glaucoma;&#x0201d; participants with vision impairment were identified by survey responses to &#x0201c;trouble seeing even with glasses or lenses&#x0201d; or &#x0201c;blind or unable to see at all.&#x0201d;</p><p id="P13">Relevant covariates included in our analysis were age, gender, race, Hispanic ethnicity, educational attainment, uninsured status, Medicare/Medicaid status, poverty ratio (a ratio of the household income to the federal poverty threshold), and self-reported prior diagnosis of a chronic medical condition (hypertension, high cholesterol, heart disease, stroke, emphysema, chronic obstructive pulmonary disease, asthma, cancer, or diabetes).</p></sec><sec id="S12"><title>Analyses</title><p id="P14">Based on NHIS design, we calculated the weighted proportions of participants for each sociodemographic group stratified by glaucoma response. Unadjusted <italic>P</italic> values from Pearson <italic>X</italic><sup><italic>2</italic></sup> tests are reported. We used separate univariable logistic regression models to determine if glaucoma diagnosis (predictor) was associated with any of the seven questions concerning cost-related barriers to medication adherence (outcome). Unadjusted negative binomial regression was used to evaluate the association of glaucoma diagnosis with the number of cost-related medication non-adherence issues.</p><p id="P15">Multivariable logistic regression was performed and adjusted for age, gender, race, ethnicity, education, medical co-morbidities, uninsured status, Medicare/Medicaid status, and poverty ratio using multiple imputation. All analyses accounted for the complex design of NHIS, including sampling weights, units, and strata, and were conducted using Stata version 16.</p></sec></sec><sec id="S13"><title>Results</title><p id="P16"><xref rid="T1" ref-type="table">Table 1</xref> presents participant characteristics. 40,380 participants were included in the study; 1,930 (weighted %: 4.0) reported having glaucoma and 38,450 (weighted %: 96.0) reported not having glaucoma. Participants with glaucoma were more likely to be female, older, black race, have another medical comorbidity, lower educational attainment, lower household income, and to have vision impairment (p&#x0003c;0.001 for all comparisons). Participants with glaucoma were less likely to be uninsured (p&#x0003c;0.001) and more likely to be insured by Medicaid (p=0.01) or Medicare (p&#x0003c;0.001) than participants without glaucoma.</p><sec id="S14"><title>Frequency of cost-related issues with medication adherence</title><p id="P17">Compared to NHIS respondents without glaucoma, those with glaucoma more frequently could not afford prescribed medication (8.2% vs 6.4% p=0.024; <xref rid="T2" ref-type="table">Table 2</xref>). Of participants with glaucoma, 22.6% had asked their doctor for lower cost medication to save money.</p><p id="P18">The adjusted predicted proportion of participants with glaucoma who had been prescribed medications was greater than among those without glaucoma (77.4% [73.8&#x02013;80.9] vs. 65.5% [64.9&#x02013;66.2], p &#x0003c;0.001). In the multivariable model, participants with glaucoma had greater cost-related barriers to medication access and more frequently endorsed all the NHIS medication cost-related statements except for &#x0201c;bought prescription drugs from another country to save money&#x0201d; (<xref rid="T2" ref-type="table">Table 2</xref>; p &#x0003c; 0.05 for all other comparisons). Both groups only had a small number of participants that bought medications from another country (1.8% [1.6&#x02013;2.0] in participants without glaucoma and 1.8% [0.8&#x02013;2.7] in participants with glaucoma, p= 0.967).</p><p id="P19">The responses to the five questions directly related to cost-related non-adherence were summed; participants with glaucoma self-reported more cost-related medication non-adherence issues than patients without glaucoma (0.32 [95%CI: 0.26&#x02013;0.39] compared to 0.24 [95% CI: 0.23&#x02013;0.25], p=0.003).</p></sec></sec><sec id="S15"><title>Discussion</title><p id="P20">In this study of a large, nationally representative sample, we found that individuals with glaucoma were more likely to face cost-related challenges that could affect medication adherence. Participants with glaucoma were more likely to report that they could not afford medications compared to those without glaucoma. Participants with glaucoma also more frequently self-reported other health co-morbidities, which likely increases medication burden. Participants with glaucoma also had lower income and lower educational attainment, which are known to affect glaucoma medication adherence.<sup><xref rid="R11" ref-type="bibr">11</xref></sup> After adjusting for co-morbidities and other potential confounders in our multivariable analyses, we found that participants with glaucoma were also significantly more likely to skip/delay/take less medication, look for alternative therapies due to the cost, and ask their doctors for lower cost medications than participants without glaucoma. When these cost-related medication non-adherence responses were aggregated, we also saw that participants with glaucoma had greater difficulties affording medications than those without glaucoma.</p><p id="P21">This analysis also highlights issues that were common among participants with and without glaucoma. Buying medications outside the US was not common among NHIS participants. The most commonly endorsed measure to address the cost burden of medications among those with glaucoma was that they &#x0201c;Asked doctor for lower cost medication to save money.&#x0201d; However, only 20% of NHIS participants asked their doctor for a lower cost medication, which is in line with previous work that demonstrated that the majority of glaucoma office visits did not involve discussions of medication cost or problems affording medications initiated by either the physician or the patient.<sup><xref rid="R12" ref-type="bibr">12</xref></sup></p><p id="P22">While some NHIS participants asked their provider for a less expensive medication, this statement does not directly imply that an individual was non-adherent to their therapy. We cannot conclude from this statement that a participant is having difficulty affording their glaucoma medication(s) or obtaining their medications. A more direct statement related to cost-related medication nonadherence was &#x0201c;Couldn&#x02019;t afford a prescribed medication,&#x0201d; which affected 8.2% of participants with glaucoma and 6.4% of participants without glaucoma, a statistically significant difference, even after adjustment for potential confounding factors.</p><p id="P23">Questions that directly called into questions an individual&#x02019;s medication adherence &#x02013; skipped medication doses to save money; took less medicine to save money; and delayed filling a prescription to save money &#x02013; were affirmed in 9.1&#x02013;12.7% of participants with glaucoma in the adjusted models. Participants with glaucoma also used alternative therapies to save (7.0% - adjusted proportion) calling into question their adherence to prescribed medication(s). In aggregate, when we summed the responses to the five questions directly related to cost-related non-adherence, participants with glaucoma self-reported greater cost-related medication non-adherence than patients without glaucoma (0.32 vs 0.24 summed responses).</p><p id="P24">Many of the strategies to decrease medication cost that were detected in the present study were also found in a previous study of a group of interviewed patients in the United Kingdom&#x02019;s National Health Service.<sup><xref rid="R13" ref-type="bibr">13</xref></sup> However, our study is the first to look at these cost-related medication adherence issues in a U.S. nationally-represented survey. Also, unlike previous studies, that had qualitatively looked at the topic of adherence, our study allows for quantification of results and comparison between those with and without self-reported glaucoma.</p><p id="P25">There are limitations to our study. For one, glaucoma diagnosis was self-reported because of the nature of this survey. Self-reported eye disease has been shown to have high specificity and low sensitivity; meaning glaucoma diagnoses may have been underestimates in this sample.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> Prevalence of glaucoma in our study was 4%, which was higher than previous historical estimates of glaucoma, however, the clinical ability to diagnose glaucoma has changed over time with advent of newer imaging modalities.<sup><xref rid="R15" ref-type="bibr">15</xref></sup> Further, our study demonstrated that participants with self-reported glaucoma were more likely to be older, have lower income, and of black race, which is consistent with results from previous epidemiological and survey studies.<sup><xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref></sup> Survey responses may also have been affected by recall and social-desirability biases. However, we would not expect these biases to affect those with and without glaucoma differently; in fact they would likely lead to underreporting of cost related medication adherence issues in NHIS, which would bias results toward the null hypothesis. Additionally, participants did not report cost-related barriers specifically related to glaucoma medications, but rather barriers to any (or all) of the medication(s) that they take. Finally, these data did not contain detail on disease severity and participant perceptions of their disease; both of which may influence the value individuals place on their glaucoma medications, which may in turn affect cost-related medication adherence issues. Some of these limitations may be able to be overcome in smaller surveys that contain greater detail on participants&#x02019; glaucoma and glaucoma treatment; though a strength of the current study is the number of participants in the NHIS survey and the generalizability of a nationally representative survey.</p><p id="P26">In data from the 2016&#x02013;2017 NHIS, a nationally representative U.S. Population survey, participants with glaucoma more frequently experienced cost-related medication issues compared to those without glaucoma. Primary care providers and eye care professionals should be prepared to discuss cost-related barriers to medication adherence with their patients who have glaucoma, and to consider alternative medications and interventions.</p></sec></body><back><ack id="S16"><title>Funding:</title><p id="P27">Joshua Ehrlich has received funding from the National Eye Institute (K23EY027848); Paula Anne Newman-Casey has received funding from the National Eye Institute (K23EY025320), Research to Prevent Blindness (Career Development Award) and the Centers for Disease Control (U01 DP006442) during the conduct of this study</p></ack><fn-group><fn id="FN1"><p id="P28"><bold>Meeting Presentation</bold>: This work was presented at the American Glaucoma Society Annual Meeting, Washington D.C., February 29, 2020</p></fn><fn id="FN2"><p id="P29" content-type="publisher-disclaimer">This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.</p></fn><fn id="FN3"><p id="P30">In this nationally representative U.S. survey, participants with glaucoma more frequently reported cost-related non-adherence to medications compared to participants without glaucoma.</p></fn><fn fn-type="COI-statement" id="FN4"><p id="P31"><bold>Conflict of Interest</bold>: None.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><name><surname>Garway-Heath</surname><given-names>DF</given-names></name>, <name><surname>Crabb</surname><given-names>DP</given-names></name>, <name><surname>Bunce</surname><given-names>C</given-names></name>, <etal/>
<article-title>Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial</article-title>. <source>Lancet</source>
<year>2015</year>; <volume>385</volume>(<issue>9975</issue>): <fpage>1295</fpage>&#x02013;<lpage>304</lpage>.<pub-id pub-id-type="pmid">25533656</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><name><surname>Okeke</surname><given-names>CO</given-names></name>, <name><surname>Quigley</surname><given-names>HA</given-names></name>, <name><surname>Jampel</surname><given-names>HD</given-names></name>, <etal/>
<article-title>Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study</article-title>. <source>Ophthalmology</source>
<year>2009</year>; <volume>116</volume>(<issue>2</issue>): <fpage>191</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">19084273</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><name><surname>Newman-Casey</surname><given-names>PA</given-names></name>, <name><surname>Blachley</surname><given-names>T</given-names></name>, <name><surname>Lee</surname><given-names>PP</given-names></name>, <name><surname>Heisler</surname><given-names>M</given-names></name>, <name><surname>Farris</surname><given-names>KB</given-names></name>, <name><surname>Stein</surname><given-names>JD</given-names></name>. <article-title>Patterns of Glaucoma Medication Adherence over Four Years of Follow-Up</article-title>. <source>Ophthalmology</source>
<year>2015</year>; <volume>122</volume>(<issue>10</issue>): <fpage>2010</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">26319441</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><name><surname>Zhao</surname><given-names>PY</given-names></name>, <name><surname>Rahmathullah</surname><given-names>R</given-names></name>, <name><surname>Stagg</surname><given-names>BC</given-names></name>, <etal/>
<article-title>A Worldwide Price Comparison of Glaucoma Medications, Laser Trabeculoplasty, and Trabeculectomy Surgery</article-title>. <source>JAMA Ophthalmol</source>
<year>2018</year>; <volume>136</volume>(<issue>11</issue>): <fpage>1271</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">30178000</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><name><surname>Friedman</surname><given-names>DS</given-names></name>, <name><surname>Hahn</surname><given-names>SR</given-names></name>, <name><surname>Gelb</surname><given-names>L</given-names></name>, <etal/>
<article-title>Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency Study</article-title>. <source>Ophthalmology</source>
<year>2008</year>; <volume>115</volume>(<issue>8</issue>): <fpage>1320</fpage>&#x02013;<lpage>7</lpage>, <comment>7 e1&#x02013;3.</comment><pub-id pub-id-type="pmid">18321582</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><name><surname>Taylor</surname><given-names>SA</given-names></name>, <name><surname>Galbraith</surname><given-names>SM</given-names></name>, <name><surname>Mills</surname><given-names>RP</given-names></name>. <article-title>Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study</article-title>. <source>J Ocul Pharmacol Ther</source>
<year>2002</year>; <volume>18</volume>(<issue>5</issue>): <fpage>401</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">12419091</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><name><surname>Tsai</surname><given-names>JC</given-names></name>, <name><surname>McClure</surname><given-names>CA</given-names></name>, <name><surname>Ramos</surname><given-names>SE</given-names></name>, <name><surname>Schlundt</surname><given-names>DG</given-names></name>, <name><surname>Pichert</surname><given-names>JW</given-names></name>. <article-title>Compliance barriers in glaucoma: a systematic classification</article-title>. <source>J Glaucoma</source>
<year>2003</year>; <volume>12</volume>(<issue>5</issue>): <fpage>393</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">14520147</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><name><surname>Lacey</surname><given-names>J</given-names></name>, <name><surname>Cate</surname><given-names>H</given-names></name>, <name><surname>Broadway</surname><given-names>DC</given-names></name>. <article-title>Barriers to adherence with glaucoma medications: a qualitative research study</article-title>. <source>Eye (Lond)</source>
<year>2009</year>; <volume>23</volume>(<issue>4</issue>): <fpage>924</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">18437182</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><name><surname>Newman-Casey</surname><given-names>PA</given-names></name>, <name><surname>Robin</surname><given-names>AL</given-names></name>, <name><surname>Blachley</surname><given-names>T</given-names></name>, <etal/>
<article-title>The Most Common Barriers to Glaucoma Medication Adherence: A Cross-Sectional Survey</article-title>. <source>Ophthalmology</source>
<year>2015</year>; <volume>122</volume>(<issue>7</issue>): <fpage>1308</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">25912144</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="web"><source>Variance Estimation Guidance NHIS 2016&#x02013;2017</source>. <month>10</month>
<day>1</day>, <year>2019</year>. <comment><ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/nchs/data/nhis/2016var.pdf">https://www.cdc.gov/nchs/data/nhis/2016var.pdf</ext-link></comment> (<comment>accessed</comment>
<date-in-citation>February 13 2020</date-in-citation>).</mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><name><surname>Dreer</surname><given-names>LE</given-names></name>, <name><surname>Girkin</surname><given-names>C</given-names></name>, <name><surname>Mansberger</surname><given-names>SL</given-names></name>. <article-title>Determinants of medication adherence to topical glaucoma therapy</article-title>. <source>J Glaucoma</source>
<year>2012</year>; <volume>21</volume>(<issue>4</issue>): <fpage>234</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">21623223</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><name><surname>Slota</surname><given-names>C</given-names></name>, <name><surname>Davis</surname><given-names>SA</given-names></name>, <name><surname>Blalock</surname><given-names>SJ</given-names></name>, <etal/>
<article-title>Patient-Physician Communication on Medication Cost during Glaucoma Visits</article-title>. <source>Optom Vis Sci</source>
<year>2017</year>; <volume>94</volume>(<issue>12</issue>): <fpage>1095</fpage>&#x02013;<lpage>101</lpage>.<pub-id pub-id-type="pmid">29194229</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><name><surname>Schafheutle</surname><given-names>EI</given-names></name>, <name><surname>Hassell</surname><given-names>K</given-names></name>, <name><surname>Noyce</surname><given-names>PR</given-names></name>, <name><surname>Weiss</surname><given-names>MC</given-names></name>. <article-title>Access to medicines: cost as an influence on the views and behaviour of patients</article-title>. <source>Health Soc Care Community</source>
<year>2002</year>; <volume>10</volume>(<issue>3</issue>): <fpage>187</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">12121255</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><name><surname>Foreman</surname><given-names>J</given-names></name>, <name><surname>Xie</surname><given-names>J</given-names></name>, <name><surname>Keel</surname><given-names>S</given-names></name>, <name><surname>van Wijngaarden</surname><given-names>P</given-names></name>, <name><surname>Taylor</surname><given-names>HR</given-names></name>, <name><surname>Dirani</surname><given-names>M</given-names></name>. <article-title>The validity of self-report of eye diseases in participants with vision loss in the National Eye Health Survey</article-title>. <source>Sci Rep</source>
<year>2017</year>; <volume>7</volume>(<issue>1</issue>): <fpage>8757</fpage>.<pub-id pub-id-type="pmid">28821861</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><name><surname>Friedman</surname><given-names>DS</given-names></name>, <name><surname>Wolfs</surname><given-names>RC</given-names></name>, <name><surname>O&#x02019;Colmain</surname><given-names>BJ</given-names></name>, <etal/>
<article-title>Prevalence of open-angle glaucoma among adults in the United States</article-title>. <source>Arch Ophthalmol</source>
<year>2004</year>; <volume>122</volume>(<issue>4</issue>): <fpage>532</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">15078671</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><name><surname>Ko</surname><given-names>F</given-names></name>, <name><surname>Boland</surname><given-names>MV</given-names></name>, <name><surname>Gupta</surname><given-names>P</given-names></name>, <etal/>
<article-title>Diabetes, Triglyceride Levels, and Other Risk Factors for Glaucoma in the National Health and Nutrition Examination Survey 2005&#x02013;2008</article-title>. <source>Invest Ophthalmol Vis Sci</source>
<year>2016</year>; <volume>57</volume>(<issue>4</issue>): <fpage>2152</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">27111561</pub-id></mixed-citation></ref></ref-list></back><floats-group><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1.</label><caption><p id="P32">Characteristics of Study Population, in NHIS participants surveyed in the years 2016&#x02013;2017.</p></caption><table frame="box" rules="all"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Characteristic</th><th align="center" valign="top" rowspan="1" colspan="1">No Glaucoma<sup><xref rid="TFN1" ref-type="table-fn">a</xref></sup></th><th align="center" valign="top" rowspan="1" colspan="1">Glaucoma<sup><xref rid="TFN1" ref-type="table-fn">a</xref></sup></th><th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> value<sup><xref rid="TFN2" ref-type="table-fn">b</xref></sup></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Total n, (weighted %)</bold></td><td align="center" valign="top" rowspan="1" colspan="1">N= 38450 (96.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">N = 1930 (4%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Age, years</bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;40&#x02013;64</td><td align="center" valign="top" rowspan="1" colspan="1">23651 (69.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">566 (33%)</td><td rowspan="4" align="center" valign="middle" colspan="1"><bold>&#x0003c;0.001</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;65&#x02013;74</td><td align="center" valign="top" rowspan="1" colspan="1">8704 (18.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">606 (30.8%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;75&#x02013;84</td><td align="center" valign="top" rowspan="1" colspan="1">4339 (8.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">487 (24.5%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;85+</td><td align="center" valign="top" rowspan="1" colspan="1">1756 (3.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">273 (11.7%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Sex</bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Male</td><td align="center" valign="top" rowspan="1" colspan="1">17382 (47.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">752 (41.4%)</td><td rowspan="2" align="center" valign="middle" colspan="1"><bold>&#x0003c;0.001</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Female</td><td align="center" valign="top" rowspan="1" colspan="1">21068 (52.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">1178 (58.6%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Race/Ethnicity</bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;White</td><td align="center" valign="top" rowspan="1" colspan="1">31765 (80.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">1457 (75.32%)</td><td rowspan="5" align="center" valign="middle" colspan="1"><bold>&#x0003c;0.001</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Black</td><td align="center" valign="top" rowspan="1" colspan="1">3967 (11.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">346 (16.9%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Asian</td><td align="center" valign="top" rowspan="1" colspan="1">1717 (5.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">69 (4.8%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;American Indian or<break/>&#x02003;Alaska Native</td><td align="center" valign="top" rowspan="1" colspan="1">376 (0.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">22 (0.9%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Multiple Race</td><td align="center" valign="top" rowspan="1" colspan="1">626 (1.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">36 (2.1%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Ethnic</bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Not Hispanic</td><td align="center" valign="top" rowspan="1" colspan="1">34839 (87.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">1758 (87.9%)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.66</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Hispanic</td><td align="center" valign="top" rowspan="1" colspan="1">3611 (12.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">172 (12.1%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Education</bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td rowspan="5" align="center" valign="middle" colspan="1">&#x0003c;<bold>0.001</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Less than high school</td><td align="center" valign="top" rowspan="1" colspan="1">4868 (12.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">342 (17.7%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">High School Diploma</td><td align="center" valign="top" rowspan="1" colspan="1">16493 (41.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">863 (44.1%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Associate Degree</td><td align="center" valign="top" rowspan="1" colspan="1">4632 (11.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">206 (10.8%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">College Graduate</td><td align="center" valign="top" rowspan="1" colspan="1">12311 (33.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">512 (27.5%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Other co-morbidity</bold><sup><xref rid="TFN3" ref-type="table-fn">c</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">27828 (69.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">1722 (88.0%)</td><td rowspan="2" align="center" valign="middle" colspan="1"><bold>&#x0003c;0.001</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">10622 (30.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">208 (12.0%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Vision impairment</bold><sup><xref rid="TFN4" ref-type="table-fn">d</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">5120 (12.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">617 (31.4%)</td><td rowspan="2" align="center" valign="middle" colspan="1"><bold>&#x0003c;0.001</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">33317 (87.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">1313 (68.6%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Uninsured</bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">2469 (7.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">50 (2.6%)</td><td rowspan="2" align="center" valign="middle" colspan="1"><bold>&#x0003c;0.001</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">35871 (92.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">1977 (97.4%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Medicaid</bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">4035 (10.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">253 (12.5%)</td><td rowspan="2" align="center" valign="middle" colspan="1"><bold>0.01</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">34341 (89.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">1674 (87.5%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Medicare</bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">15827 (33.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">1427 (69.83%)</td><td rowspan="2" align="center" valign="middle" colspan="1"><bold>&#x0003c;0.001</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">22587 (66.78%)</td><td align="center" valign="top" rowspan="1" colspan="1">503 (30.2%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Income (% of poverty level)</bold><sup><xref rid="TFN5" ref-type="table-fn">e</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0&#x02013;99.9%</td><td align="center" valign="top" rowspan="1" colspan="1">4209 (9.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">294 (13.6%)</td><td rowspan="4" align="center" valign="middle" colspan="1"><bold>&#x0003c;0.001</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">100&#x02013;199.9%</td><td align="center" valign="top" rowspan="1" colspan="1">6814 (16.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">446 (19.3%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">200&#x02013;399.9%</td><td align="center" valign="top" rowspan="1" colspan="1">11023 (27.8%))</td><td align="center" valign="top" rowspan="1" colspan="1">597 (31.8%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">400+%</td><td align="center" valign="top" rowspan="1" colspan="1">16404 (46.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">1930 (35.4%)</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>a</label><p id="P33">Participants self-report whether they have been told they have glaucoma or not in the preceding 12 months. Participants 40 years and older were included in this analysis.</p></fn><fn id="TFN2"><label>b</label><p id="P34">p-values are calculated using design-adjusted Pearson chi-squared test.</p></fn><fn id="TFN3"><label>c</label><p id="P35">Other medical diagnosis = self-reported diagnosis of hypertension, high cholesterol, heart disease, stroke, emphysema, COPD, asthma, cancer, or diabetes</p></fn><fn id="TFN4"><label>d</label><p id="P36">Vision impairment = self-reported &#x0201c;trouble seeing even with glasses or lenses&#x0201d; or &#x0201c;blind or unable to see at all&#x0201d;</p></fn><fn id="TFN5"><label>e</label><p id="P37">Multiple imputation was used for missing income (poverty level) data.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float" orientation="portrait"><label>Table 2.</label><caption><p id="P38">Unadjusted and adjusted proportions of patients with and without glaucoma that had medication cost-related issues</p></caption><table frame="box" rules="all"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th colspan="4" align="center" valign="middle" rowspan="1">Unadjusted Proportions</th></tr><tr><th align="left" valign="middle" rowspan="1" colspan="1">NHIS Question</th><th align="center" valign="middle" rowspan="1" colspan="1">No Glaucoma % [ 95% CI]</th><th align="center" valign="middle" rowspan="1" colspan="1">Glaucoma % [ 95% CI]</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic> Value<sup><xref rid="TFN7" ref-type="table-fn">b</xref></sup></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Prescribed med</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">72.8% [72.1&#x02013;73.5]</td><td align="center" valign="middle" rowspan="1" colspan="1">91.2% [89.5&#x02013;93.0]</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>&#x0003c;0.001</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Could not afford meds</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">6.4% [6.0&#x02013;6.8]</td><td align="center" valign="middle" rowspan="1" colspan="1">8.2% [6.5&#x02013;10.0]</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>0.024</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Skipped med to save</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">5.7% [5.3&#x02013;6.1]</td><td align="center" valign="middle" rowspan="1" colspan="1">6.2% [4.5&#x02013;7.8]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.598</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Took less to save</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">6.0% [5.6&#x02013;6.3]</td><td align="center" valign="middle" rowspan="1" colspan="1">6.5% [4.8&#x02013;8.2]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.539</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Delay filling</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">7.2% [6.8&#x02013;7.6]</td><td align="center" valign="middle" rowspan="1" colspan="1">8.8% [6.9&#x02013;19.6]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.088</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Asked for cheaper med</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">20.3% [19.4&#x02013;21.1]</td><td align="center" valign="middle" rowspan="1" colspan="1">22.6% [20.2&#x02013;25.0]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.053</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Bought another country</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">1.7% [1.5&#x02013;2.0]</td><td align="center" valign="middle" rowspan="1" colspan="1">1.6% [0.8&#x02013;2.5]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.828</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Alternative to save</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">4.0% [3.7&#x02013;4.2]</td><td align="center" valign="middle" rowspan="1" colspan="1">4.8% [3.5&#x02013;6.0]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.212</td></tr><tr><td colspan="4" align="center" valign="middle" rowspan="1"><bold>Adjusted Predicted Proportions</bold><sup><xref rid="TFN6" ref-type="table-fn">a</xref></sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"><bold>No Glaucoma</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>Glaucoma</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"><bold><italic>P</italic> Value</bold><sup><xref rid="TFN7" ref-type="table-fn">b</xref></sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Prescribed med</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">65.5% [64.9&#x02013;66.2]</td><td align="center" valign="middle" rowspan="1" colspan="1">77.4% [73.8&#x02013;80.9]</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>&#x0003c;0.001</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Could not afford meds</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">6.5% [6.1&#x02013;6.9]</td><td align="center" valign="middle" rowspan="1" colspan="1">8.9% [7.0&#x02013;10.8]</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>0.005</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Skipped med to save</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">6.5% [6.0&#x02013;7.0]</td><td align="center" valign="middle" rowspan="1" colspan="1">9.1% [6.6&#x02013;11.5]</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>0.016</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Took less to save</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">6.7% [6.2&#x02013;7.2]</td><td align="center" valign="middle" rowspan="1" colspan="1">9.4% [6.9&#x02013;11.8]</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>0.016</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Delay filling</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">8.1% [7.5&#x02013;8.6]</td><td align="center" valign="middle" rowspan="1" colspan="1">12.7% [10.0&#x02013;15.3]</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>&#x0003c;0.001</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Asked for cheaper med</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">20.3% [19.4&#x02013;21.2]</td><td align="center" valign="middle" rowspan="1" colspan="1">25.1% [22.6&#x02013;27.7]</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>&#x0003c;0.001</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Bought another country</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">1.8% [1.6&#x02013;2.0]</td><td align="center" valign="middle" rowspan="1" colspan="1">1.8% [0.8&#x02013;2.7]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.967</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Alternative to save</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">4.3% [4.0&#x02013;4.6]</td><td align="center" valign="middle" rowspan="1" colspan="1">7.0% [5.1&#x02013;8.9]</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>0.001</bold></td></tr></tbody></table><table-wrap-foot><fn id="TFN6"><label>a</label><p id="P39">Adjusted for: age, gender race, ethnicity, education, medical morbidities, uninsured status, Medicare/Medicaid status, and poverty ratio using multiple imputation.</p></fn><fn id="TFN7"><label>b</label><p id="P40">P values are calculated using design-adjusted Pearson chi-squared test.</p></fn></table-wrap-foot></table-wrap></floats-group></article>